PM&R
Volume 1, Issue 9 , Pages 842-851, September 2009

Chemodenervation and Nerve Blocks in the Diagnosis and Management of Spasticity and Muscle Overactivity

Received 6 August 2009; accepted 6 August 2009.

This article will discuss many of the key concepts regarding chemodenervation and neurolysis in the management of spasticity. Topics that will be discussed include techniques for localization, strengths and limitations of various agents (botulinum toxin, phenol, and alcohol), the value of combination therapies, and the role of nerve blocks (diagnostic and therapeutic). With advancing technology have come newer methods to improve accuracy of localization for the performance of chemodenervation and neurolysis such as electromyographic guidance, electrical stimulation, and ultrasound guidance. During the last 2 decades, the addition of botulinum toxin chemodenervation as an adjunct to traditional neurolysis, medication, and therapy modalities has expanded the field of treatment of intramuscular hyperactivity in upper motor neuron syndrome. The technique of diagnostic blocks as predictors of response and the therapeutic value of nerve blocks will be discussed.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  •  Disclosure: 2A, Allergan, Ipsen, and Merz; 7B, Allergan
  •  Disclosure: 7B, Allergan; 9
  • § Disclosure: nothing to disclose
  •  Disclosure: nothing to disclose
  •  Disclosure: 2A/3A, Allergan
  • # Disclosure: 3, Allergan, Cephalon, Medtronic; 7, Allergan, Medtronic, Pfizer; 8, NIDDR

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(09)00762-X

doi:10.1016/j.pmrj.2009.08.001

PM&R
Volume 1, Issue 9 , Pages 842-851, September 2009